Stocks · News reference

SELLAS Says Arbitrator Dismisses Its Claims Against 3D Medicines, Orders SELLAS To Pay Approximately $1M In Legal Fees

Jul 27, 2026, 8:42 PMBenzinga Newsdesk

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001390478/000110465926087110/tm2621415d1_8k.htm

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 2, 2026, 12:32 PMBenzinga Newsdesk
SELLAS Life Sciences Says Three Abstracts Evaluating SLS009, Potent, Selective CDK9 Inhibitor, In Preclinical Models Of PDAC Accepted For Poster Presentation At AACR Conference On Pancreatic Cancer
- Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the University of
SLS
BenzingaAug 31, 2026, 6:47 AMRadhika Anilkumar Nadig
SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED)
Short seller BMF Capital disclosed a short position in SELLAS Life Sciences, arguing the market has 'dangerously overvalued' the biotech.
MAGH RVMD SLS
BenzingaAug 29, 2026, 12:01 PMBenzinga Senior Editor
Benzinga Bulls and Bears: Nvidia, CrowdStrike, Intuit
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.
CRM CRWD INTU IREN MRVL
BenzingaAug 27, 2026, 5:13 PMVandana Singh
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
SELLAS stock gains momentum following FDA approval for Revolution Medicines, highlighting SLS009 preclinical pancreatic cancer data.
RVMD SLS